Breast cancer, stem cells and sex hormones. Part 3: The impact of the menopause and hormone replacement

Maturitas

Volumn 68, Issue 2, 2011, Pages 129-136

  Eden, John A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Breast (cancer) stem cells; Hormone (replacement) therapy; Menopause; Oestrogen; Progesterone; Progestin; Selective oestrogen receptor modulators

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PLACEBO; SEX HORMONE;

ADIPOCYTE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CANCER RISK; CANCER STEM CELL; DIET THERAPY; ESTROGEN SYNTHESIS; FIBROBLAST; HORMONE SUBSTITUTION; HUMAN; IMMUNOCOMPETENT CELL; INTRADUCTAL CARCINOMA; MENOPAUSE; NONHUMAN; TUMOR MICROENVIRONMENT;

EID: 78651388585     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.11.005     Document Type: Review

References (79)

1. J. Eden Breast cancer, stem cells and sex hormones. Part 1. The impact of fetal life and infancy Maturitas 67 2 2010 117 120
2. J. Eden Breast cancer, stem cells and sex hormones. Part 2. The impact of the reproductive years and pregnancy Maturitas 67 3 2010 215 218
3. D. Trichopoulos, H.O. Adami, A. Ekbom, C.-C. Hsieh, and P. Lagiou Early life events and conditions and breast cancer risk: from epidemiology to etiology Int J Cancer 122 3 2008 481 485
4. I. Baik, P.S. Becker, and W.J. DeVito Stem cells and prenatal origin of breast cancer Cancer Causes Control 15 2004 517 530
5. H.O. Adami, L.B. Signorello, and D. Trichopoulos Towards an understanding of breast cancer etiology Semin Cancer Biol 8 1998 255 262
6. D. Trichopoulos, P. Lagiou, and H.O. Adami The crucial role of the number of mammary tissue-specific stem cells Breast Cancer Res 7 2005 13 17
7. D. Trichopoulos, and R.D. Lipman Mammary gland mass and breast cancer risk Epidemiology 3 1992 523 526
8. J. Russo, and I.H. Russo Development of the human breast Maturitas 49 2004 2 15
9. J. Russo, G. Balogh, and I.H. Russo Breast cancer prevention Climacteric 10 Suppl. 2 2007 47 53
10. J. Russo, R. Moral, G.A. Balogh, D. Mailo, and I.H. Russo The protective role of pregnancy in breast cancer Breast Cancer Res 7 2005 131 142
11. G.A. Balogh, J. Russo, and D.A. Mailo The breast of parous women without cancer has a different genomic profile compared to those with cancer Int J Oncol 31 2007 1165 1175
12. J. Russo, G.A. Balogh, and I.H. Russo Full-term pregnancy induces a specific genomic signature in the human breast Cancer Epidemiol Biomarkers Prev 17 1 2008 51 66
13. B.E. Licznerska, P.P. Wegman, B. Nordenskjold, and S. Wingren In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients Breast Cancer Treat 112 2008 15 23
14. J.R. Pasqualini, and G.S. Chetrite Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer J Steroid Biochem Mol Biol 93 2005 221 236
15. J.A. Aka, M. Mazumdar, and S.X. Lin Reductive 17β-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer Mol Cell Endocrinol 301 2009 183 190
16. P. Stute, M. Gotte, and L. Kiesel Differential effect of hormone therapy on E1S-sulfatase activity in non-malignant and cancerous breast cells in vitro Breast Cancer Res Treat 108 2008 363 374
17. T. Suzuki, Y. Miki, J. Akahira, T. Moriya, N. Ohuchi, and H. Sasano Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations Endocr J 55 3 2008 455 463
18. B.G. Wren Do female sex hormones initiate breast cancer? A review of the evidence Climacteric 7 2004 120 128
19. T. Suzuki, Y. Miki, and Y. Nakamura Sex steroid-producing enzymes in human breast cancer Endocr Relat Cancer 12 2005 701 720
20. R.B. Clarke Ovarian steroids and the human breast: regulation of stem cells and cell proliferation Maturitas 54 2006 327 333
21. H.L. LaMarca, and J.M. Rosen Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage Breast Cancer Res 9 2007 304 307
22. N.A. Mousa, and R.F. Casper Menopausal estrogen deprivation activates steroid sensitive stem cells (3SC) and local estrogen biosynthesis: a model for breast cancer development Biosci Hypotheses 2 2009 252 256
23. N. Patani, B. Cutuli, and K. Mokbel Current management of DCIS: a review Breast Cancer Res Treat 111 2008 1 10
24. B.A. Virnig, T.M. Tuttle, T. Shamliyan, and R.L. Kane Ductal carcinoma in situ of the breast: systematic review of incidence, treatment, and outcomes JNCI 102 3 2010 170 178
25. J.C. Boughey, R.J. Gonzales, E. Bonner, and H.M. Kuerer Current treatment and clinical trial developments for ductal carcinoma in situ of the breast Oncologist 12 2007 1276 1287
26. B. Erbas, E. Provenzano, J. Armes, and D. Gertig The natural history of ductal carcinoma in situ of the breast: a review Breast Cancer Res Treat 97 2006 135 144
27. H.G. Welch, and Black WC Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127 1997 1023 1028
28. V. Espina, B.D. Mariani, and R.I. Gallagher Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival PLoS ONE 5 4 2010 e10240
29. I. Mercier, M.C. Casimiro, and J. Zhou Genetic ablation of caveolin-1 drives oestrogen-hypersensitivity and the development of DCIS-like mammary lesions Am J Pathol 174 4 2009 1172 1190
30. J.A. Engelman, X.L. Zhang, and M.P. Lisanti Genes encoding human caveolin-1 and -2 are colocalized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers FEBS Lett 436 1998 403 410
31. J.A. Engelman, X.L. Zhang, and M.P. Lisanti Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5 promoter region of the caveolin-1 gene in human breast cancer cell lines FEBS Lett 448 1999 221 230
32. A.K. Witkiewicz, A. Dasupta, and K.H. Nguyen Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer Cancer Biol Ther 8 11 2009 1071 1079
33. P.C. Nowell The clonal evolution of tumor cell populations Science 194 1976 23 28
34. P. Dalerba, R.W. Cho, and M. Clarke Cancer stem cells: models and concepts Annu Rev Med 58 2007 267 284
35. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 2003 3983 3988
36. C. Ginestier, M.H. Hur, and E. Charafe-Jauffret ALDHI is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 2007 555 567
37. E. Charafe-Jauffret, C. Ginestier, and F. Iovino Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signal Cancer Res 69 4 2009 1302 1313
38. A.M. Cheung, T.S. Wan, and J.C. Leung Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential Leukemia 21 2007 1423 1430
39. S. Corti, F. Locatelli, and D. Papadimitriou Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity Stem Cells 24 2006 975 985
40. T. Tanei, K. Morimoto, and K. Shimazu Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy Clin Cancer Res 15 12 2009 4234 4241
41. R. Villadsen, A.J. Fridriksdottir, and L. Ronnov-Jessen Evidence for a stem cell hierarchy in the adult human breast J Cell Biol 177 2007 87 101
42. F.L. Muehlberg, Y.H. Song, and A. Krohn Tissue-resident stem cells promote breast cancer growth and metastasis Carcinogenesis 30 4 2009 589 597
43. L. Vona-Davis, and D.P. Rose Angiogenesis, adipokines and breast cancer Cytokine Growth Factor Rev 20 2009 193 201
44. L. Ronnov-Jessen, and M.J. Bissell Breast cancer by proxy: can the microenvironment be both the cause and the consequence? Trends Mol Med 15 1 2009 5 13
45. B. Weigelt, and M.J. Bissell Unraveling the microenvironmental influences on the normal mammary gland and breast cancer Semin Cancer Biol 18 2008 311 321
46. Y. Yamaguchi, and S.I. Hayashi Estrogen-related microenvironment of breast cancer Endocr J 56 1 2009 1 7
47. N.A. Bhowmick, E.G. Neilson, and H.L. Moses Stromal fibroblasts in cancer initiation and progression Nature 432 2004 332 337
48. G. Chetrite, C. Varin, L. Delalonde, and J.R. Pasqualini Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the oestrone sulphatase activity of human breast cancer cells Anticancer Res 13 4 1993 931 934
49. E. Ritter, A. Perry, J. Yu, T. Wang, L. Tang, and E. Bieberich Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells Ann Surg 247 2008 310 314
50. A.W. Cohen, R. Hnasko, W. Schubert, and M.P. Lisanti Role of caveolae and caveolins in health and disease Physiol Rev 84 2004 1341 1379
51. B. Rzani, S.E. Woodman, and M.P. Lisanti Caveolae: from cell biology to animal physiology Pharmacol Rev 54 2002 431 467
52. F. Sotgia, H. Rui, G. Bonuccelli, I. Mercier, R.G. Pestell, and M.P. Lisanti Caveolin-1, mammary stem cells and oestrogen-dependent breast cancers Cancer Res 66 22 2006 10647 10651
53. G. Bonuccelli, M.C. Casimiro, and F. Sotgia Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature Am J Pathol 174 2009 1650 1662
54. M. Santisteban, J.M. Reiman, and M.K. Asiedu Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells Cancer Res 69 7 2009 2887 2895
55. N. Honma, K. Takubo, and M. Sawabe Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years J Clin Endocrinol Metab 91 2006 607 613
56. E.R. Simpson, M. Misso, and K.N. Hewitt Estrogen - the good, the bad, and the unexpected Endocr Rev 26 3 2005 322 330
57. A. Eisen, M. Trudeau, W. Shelley, H. Messersmith, and K.I. Pritchard Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systemic review Cancer Treat Rev 34 2008 157 174
58. C.M. Greiser, E.M. Greiser, and M. Dören Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials Hum Reprod Update 11 6 2005 561 573
59. F.P. Chen Postmenopausal hormone therapy and risk of breast cancer Chang Gung Med J 32 2009 140 147
60. J. Cusack Hormone replacement therapy Eur J Cancer 44 2008 2344 2349
61. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 321 333
62. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
63. M.L. Stefanick, G.L. Anderson, and K.L. Margolis Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy JAMA 295 2006 1647 1657
64. Eden JA. Why does oestrogen-only hormone therapy have such a small impact on breast cancer risk? A hypothesis. Gynecol Endocrinol, in press.
65. A.O. Mueck, H. Seeger, and D. Wallwiener Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogens addition Climacteric 6 2003 221 227
66. J. Eden Progestins and breast cancer risk Am J Obstet Gynecol 188 5 2003 1123 1131
67. K.B. Horwitz, W.W. Dye, J.C. Harrell, P. Kabos, and C.A. Sartorius Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts Proc Natl Acad Sci USA 105 2008 5774 5779
68. K.B. Horwitz, and C.A. Sartorius Progestins in hormone replacement therapies reactivate cancer stem cells in women with pre-existing breast cancers: a hypothesis J Clin Endocrinol Metab 93 2008 3295 3298
69. K.B. Horwitz The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk Mol Endocrinol 22 2008 2743 2750
70. C.A. Sartorius, D.M.E. Harvell, T. Shen, and K.B. Horwitz Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth Cancer Res 65 2005 9779 9788
71. World Cancer Research Fund/The American Institute for Cancer Research Food, nutrition, physical activity and the prevention of cancer: a global perspective 2007 World Cancer Research Fund International
72. L. Ross, R.L. Prentice, and B. Caan Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative randomized controlled dietary modification trial JAMA 295 2006 629 642
73. S.L. Neuhausen, E. Matloff, and R. Eeles Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality JAMA 304 9 2010 967 975
74. S.R. Cummings, J.A. Tice, and S. Bauer Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk JNCI 101 6 2009 384 398
75. B. Arun, B.K. Dunn, L.G. Ford, and A. Ryan Breast cancer prevention trials: large and small trials Semin Oncol 37 4 2010 367 383
76. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
77. E. Barrett-Connor, J.A. Cauley, P.M. Kulkarni, A. Sashegyi, D.A. Cox, and M.J. Geiger Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial J Bone Miner Res 19 8 2004 1270 1275
78. S. Martino, J.A. Cauley, and E. Barrett-Connor Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 96 2004 1751 1761
79. A.Y. Ting, B.F. Kimler, C.J. Fabian, and B.K. Petroff Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases Cancer Prev Res 1 7 2008 546 553